Aptamers Market Analysis

Aptamers Market Analysis

To get key market trends

  Download Free Sample

By type, the aptamers market is classified into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The DNA-based aptamers segment accounted for 63.4% of the industry share in 2022. DNA-based aptamers, derived from DNA sequences, offer a versatile and well-established platform for a wide array of applications. Their unique characteristics, such as stability, cost-effectiveness, and ease of synthesis, have increased their demand in healthcare industry. Furthermore, recent progress in the development, purification, and targeted delivery of aptamers to eliminate specific cells has captured the interest of numerous researchers.
 

Based on application, the aptamers market is segmented into research & development, diagnostics, therapeutics, and other applications. The research & development segment accounted for 35.6% of the industry share in 2022. With an increasing focus on innovation and cutting-edge solutions, aptamers have emerged as a powerful resource within the R&D landscape. The adaptability of aptamers, coupled with ongoing advancements in selection methodologies and customization techniques, has captured the attention of both academia and industry players. Moreover, collaborative efforts between researchers, biotechnology firms, and institutions are fostering an environment of exploration and discovery. For instance, in June 2021, SomaLogic collaborated with Ixaka Ltd to support the discovery and development of aptamers based bispecific therapeutics.
 

Based on technology, the aptamers market is segmented into SELEX, X-aptamers, and other technologies. The SELEX segment is projected to witness significant progressF of 19.9% by 2032. SELEX's unique capability to systematically identify high-affinity aptamers for diverse targets offers a strategic advantage in the development of aptamer-based solutions. Also, SELEX involves a methodical process of selection, amplification, and refinement, empowering researchers to craft aptamers for precise binding. Moreover, the continuous enhancements in SELEX methodologies coupled with SELEX's role in enabling the creation of innovative diagnostics, therapeutics, and research tools has fuelled its widespread adoption.
 

Based on end-use, the aptamers market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, research institutes, and other end-users. The pharmaceutical & biotechnology companies segment is projected to witness significant growth of 20.3% by 2032. Increasing investments in pharmaceutical research & development will significantly drive the aptamer industry by catalysing innovation and accelerating the development of aptamer-based solutions. For instance, in June 2018, Aptamer Group Ltd received USD 2.2 million from Meneldor, a biopharmaceutical investment company and other overseas investors. This fund was utilized to drive preclinical discovery programs involving the development of aptamer drug conjugates.
 

North America aptamers market accounted for 43.6% industry share in 2022. The region's well-established pharmaceutical and biotechnology industry, along with the presence of prominent research institutes, academic centers, and well-funded healthcare initiatives. Moreover, the growing prevalence of chronic diseases such as cancer, cardiovascular disease (CVD) and age-related macular degeneration (AMD). Additionally, the region's proactive regulatory landscape and supportive policies facilitate efficient development, validation, and commercialization of aptamer-based products.